title: In vivo effect of recombinant human granulocyte colony-stimulating factor on neutrophilic expression of CD11b in septic neonates: a randomized controlled trial.
abstract: Neonates are susceptible to septicemia secondary to quantitative and qualitative neutrophilic defects. Granulocyte colony-stimulating factor (G-CSF) stimulates myeloid progenitor cell proliferation and induces selective neutrophil functions. The authors aimed to evaluate the effect of G-CSF administration in septic neonates on neutrophil production and CD11b expression. Sixty septic neonates were randomized to receive intravenous G-CSF 10 μg/kg/day for 3 days (G-CSF group, n = 30), or not to receive G-CSF (non-G-CSF group, n = 30). Thirty healthy newborns were included as controls. Laboratory investigations included complete blood count, C-reactive protein, blood culture, renal and liver function tests, and assessment of neutrophilic expression of CD11b. Total leukocytes count (TLC), absolute neutrophil count (ANC), and immature myeloid cell count in G-CSF group showed significant difference between post-and pre-G-CSF levels. TLC, ANC, immature myeloid cell count and immature/total myeloid cells ratio were higher in G-CSF group compared to non-G-CSF group on days 1 and 3. Higher neutrophilic expression of CD11b was reported in both septic groups on day 0 compared to control group. On day 5, CD11b was higher in G-CSF group than non-G-CSF group. G-CSF improved CD11b% in neutropenic and non-neutropenic septic neonates. No significant difference was found between pre- and posttreatment renal and liver function tests. Lower duration of antibiotic intake and hospitalization was observed in G-CSF group compared to non-G-CSF group. G-CSF administration as an adjuvant therapy for neonatal septicemia, whether neutropenic or not, improves neutrophilic count and function and contributed to early healing from sepsis.
authors.affiliation: Pediatric Department, Ain Shams University, Cairo, Egypt.
authors.forename: Mona M
authors.initials: MM
authors.lastname: El-Ganzoury
authors.forename: Rania A
authors.initials: RA
authors.lastname: El-Farrash
authors.forename: Abeer A
authors.initials: AA
authors.lastname: Saad
authors.forename: Ashraf G
authors.initials: AG
authors.lastname: Mohamed
authors.forename: Inji G
authors.initials: IG
authors.lastname: El-Sherbini
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001772:Blood Cell Count; D039481:CD11b Antigen / Q000096:biosynthesis / Q000235:genetics*; D049109:Cell Proliferation / Q000187:drug effects; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D006760:Hospitalization; D006801:Humans; D007231:Infant, Newborn; D009504:Neutrophils / Q000378:metabolism* / Q000473:pathology; D018805:Sepsis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D039481:CD11b Antigen; C509295:ITGAM protein, human; D016179:Granulocyte Colony-Stimulating Factor